Jefferies analyst Matthew Taylor maintains $Boston Scientific (BSX.US)$ with a buy rating, and adjusts the target price from $90 to $100.
According to TipRanks data, the analyst has a success rate of 58.7% and a total average return of 9.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific's recent quarterly results exceeded expectations on all fronts, despite already high anticipations. The company's stock, however, is experiencing pressure due to the temporary halt of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment not currently being treated. It's noteworthy that this pause is for evaluative purposes, and the trial's enrollment is anticipated to recommence shortly.
Boston Scientific is recognized for possessing one of the most comprehensive pipelines in the medtech sector, with a significant portion of its revenue growth contributing positively to margins. The increased confidence in the company's growth prospects and the sustainability of its double-digit revenue expansion justify a heightened valuation multiple.
The AVANT Guard trial setback is not associated with a mortality event or initiated by the FDA, and there is an expectation that the global Farapulse momentum will continue over the medium-term. It's suggested that the pullback in Boston Scientific shares offers an attractive entry point for investors.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Matthew Taylor維持$波士頓科學 (BSX.US)$買入評級，並將目標價從90美元上調至100美元。
根據TipRanks數據顯示，該分析師近一年總勝率為58.7%，總平均回報率為9.3%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
儘管預期已經很高，但波士頓科學最近的季度業績在各個方面都超出了預期。但是，由於Avant GUARD臨床試驗暫時停止，該公司的股票承受壓力。該試驗正在對目前尚未接受治療的新患者群體的Farapulse進行調查。值得注意的是，此次暫停是出於評估目的，預計該試驗的註冊將很快重新開始。
波士頓科學因擁有醫療技術領域最全面的產品線之一而聞名，其收入增長的很大一部分爲利潤率做出了積極貢獻。對公司增長前景的信心增強及其兩位數收入擴張的可持續性證明了估值倍數的提高是合理的。
Avant Guard試驗的挫折與死亡事件無關，也與美國食品藥品管理局發起無關，預計全球Farapulse的勢頭將在中期內持續下去。有人認爲，波士頓科學股票的回調爲投資者提供了一個有吸引力的切入點。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
